Clinical validity and intrarater and test–retest reliability of the Structured Clinical Interview for DSM‐5 – Clinician Version (SCID‐5‐CV)
Flávia de Lima Osório(Conselho Nacional de Desenvolvimento Científico e Tecnológico), José Alexandre S. Crippa(Universidade de Ribeirão Preto), Rocío Martín‐Santos(Centro de Investigación Biomédica en Red de Salud Mental), Ana Paula Casagrande Silva‐Rodrigues(Clinics Hospital of Ribeirão Preto), Thiago D. Apolinario(Clinics Hospital of Ribeirão Preto), Fernanda Aguiar Pizeta, Victor S. Fracon(Clinics Hospital of Ribeirão Preto), Rafael G. dos Santos(Clinics Hospital of Ribeirão Preto), João Paulo Machado‐de‐Sousa(Conselho Nacional de Desenvolvimento Científico e Tecnológico), Lívia Maria Bolsoni(Universidade de São Paulo), Juliana Mayumi Ushirohira(Clinics Hospital of Ribeirão Preto), Sônia Regina Loureiro(Universidade de São Paulo), Cristiane von Werne Baes(Clinics Hospital of Ribeirão Preto), Jaime E. C. Hallak(Universidade de Ribeirão Preto), Roberto Mascarenhas Souza, Rafael Faria Sanches(Universidade de Ribeirão Preto), Thiago M. Guimarães, Mariana Fortunata Donadon
Cited by 338
Related Papers
Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial
|Psychological Medicine|2018|819
Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients
|Neuropsychopharmacology|2011|763
Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report
|Journal of Psychopharmacology|2010|530
Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report
|Brazilian Journal of Psychiatry|2015|484
Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression
|Journal of Clinical Psychopharmacology|2015|465